6533b83afe1ef96bd12a7b89

RESEARCH PRODUCT

Cigarette smoking and risk of Hodgkin lymphoma and its subtypes: a pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymph)

John R. MclaughlinJohn R. MclaughlinShelia Hoar ZahmMads Kamper-jørgensenMads Kamper-jørgensenHenrik HjalgrimJohn J. SpinelliJohn J. SpinelliTongzhang ZhengC. La VecchiaC. La VecchiaN BeckerPunam PahwaSally L. GlaserSally L. GlaserPaolo BoffettaEllen T. ChangEllen T. ChangLenka ForetováPierluigi CoccoKlaus RostgaardWendy CozenJames A. DosmanLucia MiligiAlexandra NietersDiego SerrainoPaolo VineisAlain MonnereauPaul BrennanKarin E. SmedbyAnthony StainesMarc MaynadiéEleanor KaneMartine VornanenS. Sanjose

subject

AdultMaleRiskOncologyEpstein-Barr Virus InfectionsHerpesvirus 4 Humanmedicine.medical_specialtyAdolescentReviewscigarette smokingYoung AdultNodular sclerosisRisk FactorsInternal medicineEpidemiologycase–controlmedicineHumansEpstein–Barr viruindividual patient data meta-analysisYoung adultAgedAged 80 and overbusiness.industrySmokingConfoundingCase-control studyTobacco Use DisorderHematologyOdds ratioMiddle Agedmedicine.diseaseHodgkin DiseaseLymphomaSocial ClassOncologyCase-Control StudiesImmunologyEtiologyFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieepidemiologybusinessHodgkin lymphoma

description

Kamper-Jorgensen, M Rostgaard, K Glaser, S L Zahm, S H Cozen, W Smedby, K E Sanjose, S Chang, E T Zheng, T La Vecchia, C Serraino, D Monnereau, A Kane, E V Miligi, L Vineis, P Spinelli, J J McLaughlin, J R Pahwa, P Dosman, J A Vornanen, M Foretova, L Maynadie, M Staines, A Becker, N Nieters, A Brennan, P Boffetta, P Cocco, P Hjalgrim, H eng 5 ROI CA69269/CA/NCI NIH HHS/ Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't England 2013/06/22 06:00 Ann Oncol. 2013 Sep;24(9):2245-55. doi: 10.1093/annonc/mdt218. Epub 2013 Jun 19.; International audience; BACKGROUND: The etiology of Hodgkin lymphoma (HL) remains incompletely characterized. Studies of the association between smoking and HL have yielded ambiguous results, possibly due to differences between HL subtypes. PATIENTS AND METHODS: Through the InterLymph Consortium, 12 case-control studies regarding cigarette smoking and HL were identified. Pooled analyses on the association between smoking and HL stratified by tumor histology and Epstein-Barr virus (EBV) status were conducted using random effects models adjusted for confounders. Analyses included 3335 HL cases and 14 278 controls. RESULTS: Overall, 54.5% of cases and 57.4% of controls were ever cigarette smokers. Compared with never smokers, ever smokers had an odds ratio (OR) of HL of 1.10 [95% confidence interval (CI) 1.01-1.21]. This increased risk reflected associations with mixed cellularity cHL (OR = 1.60, 95% CI 1.29-1.99) and EBV-positive cHL (OR = 1.81, 95% CI 1.27-2.56) among current smokers, whereas risk of nodular sclerosis (OR = 1.09, 95% CI 0.90-1.32) and EBV-negative HL (OR = 1.02, 95% CI 0.72-1.44) was not increased. CONCLUSION: These results support the notion of etiologic heterogeneity between HL subtypes, highlighting the need for HL stratification in future studies. Even if not relevant to all subtypes, our study emphasizes that cigarette smoking should be added to the few modifiable HL risk factors identified.

yearjournalcountryeditionlanguage
2013-01-01Annals of Oncology
https://doi.org/10.1093/annonc/mdt218